Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Cash Flow (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Net Cash Flow for 6 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 130.59% to $11.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$90.0 million through Dec 2025, up 9.84% year-over-year, with the annual reading at -$89.1 million for FY2025, 10.7% up from the prior year.
  • Net Cash Flow for Q4 2025 was $11.7 million at 4D Molecular Therapeutics, up from -$28.6 million in the prior quarter.
  • The five-year high for Net Cash Flow was $157.7 million in Q2 2023, with the low at -$152.8 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$10.9 million, with a median of -$16.0 million recorded in 2021.
  • The sharpest move saw Net Cash Flow surged 859.1% in 2023, then plummeted 1779.37% in 2025.
  • Over 5 years, Net Cash Flow stood at $62.0 million in 2021, then tumbled by 190.22% to -$55.9 million in 2022, then soared by 52.51% to -$26.6 million in 2023, then crashed by 43.78% to -$38.2 million in 2024, then skyrocketed by 130.59% to $11.7 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $11.7 million, -$28.6 million, and -$57.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.